论文部分内容阅读
目的:探讨瑞舒伐他汀联合曲美他嗪对冠心病预后心血管事件及安全性的影响。方法:选取茂名石化医院2014年4月-2015年2月收治的110例冠心病患者,依据数字随机表法分为观察组和对照组,每组55例患者。对照组单独使用瑞舒伐他汀进行治疗,观察组在对照组的基础上进行曲美他嗪的治疗,观察并对比两组患者心血管事件及安全性的情况。结果:观察组并发症显著少于对照组,6 min步行大于425 m的人数显著多于对照组,小于150 m的人数少于对照组,差异具有统计学意义(P<0.05)。结论:瑞舒伐他汀联合曲美他嗪对冠心病患者进行治疗,能有效减少心血管事件发生并提高安全性。
Objective: To investigate the effect of rosuvastatin combined with trimetazidine on cardiovascular events and safety of patients with coronary heart disease. Methods: A total of 110 patients with coronary heart disease admitted from April 2014 to February 2015 in Maoming Petrochemical Hospital were divided into observation group and control group according to the digital random table method, with 55 patients in each group. The control group was treated with rosuvastatin alone. The observation group was treated with trimetazidine on the basis of the control group. The cardiovascular events and safety of the two groups were observed and compared. Results: The complication of the observation group was significantly less than that of the control group. The number of walking greater than 425 m at 6 min was significantly more than that of the control group. The number of patients less than 150 m was less than that of the control group. The difference was statistically significant (P <0.05). Conclusion: Rosuvastatin combined with trimetazidine treatment of coronary heart disease patients, can effectively reduce the incidence of cardiovascular events and improve safety.